NasdaqCM - Nasdaq Real Time Price USD

NeuroOne Medical Technologies Corporation (NMTC)

0.6141

-0.0070

(-1.13%)

At close: April 29 at 4:00:00 PM EDT

0.6400

+0.03

+(4.22%)

After hours: April 29 at 7:56:34 PM EDT

NeuroOne® Completes FDA Submission for the OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain

Multi-Contact Probe Provides Alternative to Pharmaceutical and Invasive Surgical Treatments Submission Completed Earlier Than Anticipated EDEN PRAIRIE, Minn., April 23, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, has filed its 510(k) submission to the FDA for trigeminal nerve ablation earlier

GlobeNewswire 6 days ago

NMTC
-1.13%
NeuroOne® Issues Letter to Shareholders

Company Now Fully Funded Through at least Fiscal 2026; Company Confirms No Material Impact from Global Tariffs EDEN PRAIRIE, Minn., April 16, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, has issued a letter to shareholders from CEO, Dave Rosa. Dear Shareholders, In recent months, NeuroOne has a

GlobeNewswire 13 days ago

NMTC
-1.13%
NeuroOne® OneRF® Technology Success Story Featured on Fox News

Pediatric Patient Treated with OneRF® Ablation System Goes From Up to 10 Nightly Seizures to Zero EDEN PRAIRIE, Minn., April 14, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today that its proprietary OneRF® Ablation System was recently featured in a national Fox News article highligh

GlobeNewswire 15 days ago

NMTC
-1.13%
Ronald McClurg Spends US$100k On NeuroOne Medical Technologies Stock

Whilst it may not be a huge deal, we thought it was good to see that the NeuroOne Medical Technologies Corporation...

Simply Wall St. 19 days ago

NMTC
-1.13%
NeuroOne Medical Technologies Corporation Announces Pricing of $8.0 Million Public Offering of Common Stock

EDEN PRAIRIE, Minn., April 04, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today the pricing of an underwritten registered public offering of 16,000,000 shares of its common stock at a price of $0.50 per share. Ladenburg Thalmann & Co. Inc. is acting as sole book-running manager for the offering.

GlobeNewswire 25 days ago

NMTC
-1.13%
NeuroOne Medical Technologies Corporation Announces Proposed Public Offering of Common Stock

EDEN PRAIRIE, Minn., April 03, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today that it has commenced a proposed underwritten registered public offering of shares of its common stock. All of the shares of common stock to be sold in the proposed offering will be sold by the Company. In addition, t

GlobeNewswire 26 days ago

NMTC
-1.13%
NeuroOne® CEO Dave Rosa Discusses Epilepsy Treatment Innovations on Today’s Marketplace - Update

EDEN PRAIRIE, Minn., March 18, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today that CEO Dave Rosa was featured on Today’s Marketplace (TMP) alongside Dr. Jessica Clark, DNP, RN, Dean of the College of Nursing at Creighton University. The discussion explored the latest advancements

GlobeNewswire last month

NMTC
-1.13%
NeuroOne® CEO Dave Rosa Discusses Epilepsy Treatment Innovations on Today’s Marketplace

EDEN PRAIRIE, Minn., March 18, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today that CEO Dave Rosa was featured on Today’s Marketplace (TMP) alongside Dr. Jessica Clark, DNP, RN, Dean of the College of Nursing at Creighton University. The discussion explored the latest advancements

GlobeNewswire last month

NMTC
-1.13%
NeuroOne CEO Joins Today’s Marketplace To Discuss The Latest Treatments for Epilepsy

NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Today's Marketplace (TMP) is proud to announce a featured interview with NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) CEO Dave Rosa and Jessica Clark, DNP, RN, Dean of the College of Nursing at Creighton University. The pair joined Today’s Marketplace host Elizabeth Hart to discuss the latest treatments for epilepsy The full interview can be viewed online here. “Epilepsy is a neurological condition," explained Dr. Clark. “Right now we are

GlobeNewswire last month

NMTC
-1.13%
NeuroOne® Accelerates Timeline of 510(k) Submission to FDA for the OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain

Submission for New Intended Use That Leverages Company’s Patented OneRF® Technology Platform Expected in May 2025 EDEN PRAIRIE, Minn., March 11, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, has accelerated the anticipated timeline of its 510(k) submission to the FDA for trigeminal nerve ablatio

GlobeNewswire last month

NMTC
-1.13%
NeuroOne® to Present at the Oppenheimer 35th Annual Healthcare MedTech & Services Conference

EDEN PRAIRIE, Minn., March 05, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced that it will participate in the upcoming Oppenheimer 35th Annual Healthcare Conference MedTech & Services Conference on Wednesday, March 19, 2025. NeuroOne CEO Dave Rosa will host a virtual corporate presentat

GlobeNewswire last month

NMTC
-1.13%
NeuroOne® Reports First Quarter Fiscal Year 2025 Financial Results and Provides Corporate Update

Total revenue of $6.3M Includes $3.3 Million of Product Revenue in Addition to a One-Time Upfront Payment of $3.0 Million in License Revenue from Zimmer Biomet EDEN PRAIRIE, Minn., Feb. 12, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, has reported financial results for the first quarter fiscal year 2025 ended De

GlobeNewswire 2 months ago

NMTC
-1.13%
NeuroOne® to Report First Quarter Fiscal Year 2025 Financial Results on Wednesday, February 12 at 8:30 a.m. Eastern Time

EDEN PRAIRIE, Minn., Feb. 05, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will release financial results for its fiscal first quarter ended December 31, 2024, before market open on February 12, 2025. Management will host an investor conference call and webcast at 8:30 a.m. eastern time on Wedn

GlobeNewswire 2 months ago

NMTC
-1.13%
NeuroOne® Regains Compliance with Nasdaq Listing Requirements

EDEN PRAIRIE, Minn., Feb. 04, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it has regained compliance with the Nasdaq Capital Market’s continued listing standard for the minimum share price requirements under Nasdaq Listing Rule 5550(a)(2). The Company received a letter on

GlobeNewswire 2 months ago

NMTC
-1.13%
NeuroOne Reports Record Revenue Boost in Q1 2025

NeuroOne Medical Technologies ( (NMTC) ) has shared an update. NeuroOne announced a preliminary unaudited revenue increase for the first quarter of fiscal 2025 to a record $6.2 million, significantly up from $1 million in the previous year. The revenue boost includes a $3 million upfront payment from an expanded distribution agreement with Zimmer Biomet for the OneRF™ Ablation System, along with a 227% increase in product revenue to $3.2 million, which reflects the company’s strengthened market

TipRanks 3 months ago

NMTC
-1.13%
NeuroOne® Announces Preliminary Unaudited First Quarter Fiscal 2025 Revenue Increase to a Record $6.2 Million

First Quarter Fiscal 2025 Revenue Includes a One-Time Upfront Payment of $3.0 Million in Collaboration Revenue from Zimmer Biomet and $3.2M in Product Revenue Management to Host Virtual Investor Webinar Today at 11:00 a.m. Eastern Time EDEN PRAIRIE, Minn., Jan. 10, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurolog

GlobeNewswire 3 months ago

NMTC
-1.13%
NeuroOne® Announces Change of Virtual Investor Webinar to Friday, January 10, 2024

Company to Provide Overview of Business Model and Expected Revenue Acceleration in Fiscal Year 2025 EDEN PRAIRIE, Minn., Jan. 06, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today a change to its Virtual Investor Webinar date due to U.S. equity markets being closed for the National D

GlobeNewswire 3 months ago

NMTC
-1.13%
NeuroOne® Announces Virtual Investor Webinar on January 9, 2025 at 11:00 a.m. EST

Company to Provide Overview of Business Model and Expected Revenue Acceleration in Fiscal Year 2025 EDEN PRAIRIE, Minn., Jan. 03, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today that it will hold a virtual roadshow webinar to discuss its business operations and recent updates. Dave

GlobeNewswire 3 months ago

NMTC
-1.13%
NeuroOne® Product Revenue Increases 77% to $3.5 Million in Fiscal 2024: Expects Product Revenue to Increase at Least 132% to at Least $8 Million in Fiscal 2025

Company’s Exclusive Distribution Agreement with Zimmer Biomet included $3.0 Million Upfront Payment: Expected to Drive Revenue and Expand Margins Significantly EDEN PRAIRIE, Minn., Dec. 17, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, has reported financial results for the fourth quarter and fiscal year ended Se

GlobeNewswire 4 months ago

NMTC
-1.13%
NeuroOne® to Report Fourth Quarter and Fiscal Year 2024 Financial Results on December 17 at 9:00 a.m. Eastern Time

EDEN PRAIRIE, Minn., Dec. 04, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will release financial results for the fiscal fourth quarter and year ended September 30, 2024, before market open on December 17, 2024. Management will host an investor conference call and webcast at 9:00 a.m. Eastern t

GlobeNewswire 4 months ago

NMTC
-1.13%

Performance Overview

Return	NMTC	S&P 500 (^GSPC)
YTD	-25.65%	-5.45%
1-Year	-45.17%	+8.69%
3-Year	-20.25%	+34.58%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

NeuroOne Medical Technologies Corporation (NMTC)

NeuroOne® Completes FDA Submission for the OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain

NeuroOne® Issues Letter to Shareholders

NeuroOne® OneRF® Technology Success Story Featured on Fox News

Ronald McClurg Spends US$100k On NeuroOne Medical Technologies Stock

NeuroOne Medical Technologies Corporation Announces Pricing of $8.0 Million Public Offering of Common Stock

NeuroOne Medical Technologies Corporation Announces Proposed Public Offering of Common Stock

NeuroOne® CEO Dave Rosa Discusses Epilepsy Treatment Innovations on Today’s Marketplace - Update

NeuroOne® CEO Dave Rosa Discusses Epilepsy Treatment Innovations on Today’s Marketplace

NeuroOne CEO Joins Today’s Marketplace To Discuss The Latest Treatments for Epilepsy

NeuroOne® Accelerates Timeline of 510(k) Submission to FDA for the OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain

NeuroOne® to Present at the Oppenheimer 35th Annual Healthcare MedTech & Services Conference

NeuroOne® Reports First Quarter Fiscal Year 2025 Financial Results and Provides Corporate Update

NeuroOne® to Report First Quarter Fiscal Year 2025 Financial Results on Wednesday, February 12 at 8:30 a.m. Eastern Time

NeuroOne® Regains Compliance with Nasdaq Listing Requirements

NeuroOne Reports Record Revenue Boost in Q1 2025

NeuroOne® Announces Preliminary Unaudited First Quarter Fiscal 2025 Revenue Increase to a Record $6.2 Million

NeuroOne® Announces Change of Virtual Investor Webinar to Friday, January 10, 2024

NeuroOne® Announces Virtual Investor Webinar on January 9, 2025 at 11:00 a.m. EST

NeuroOne® Product Revenue Increases 77% to $3.5 Million in Fiscal 2024: Expects Product Revenue to Increase at Least 132% to at Least $8 Million in Fiscal 2025

NeuroOne® to Report Fourth Quarter and Fiscal Year 2024 Financial Results on December 17 at 9:00 a.m. Eastern Time

Performance Overview